Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUALIS
2015-000360-34Phase 3Terminated
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of darunavir, ritonavir, dolutegravir, abacavir, lamivudine and 3 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Technical University of Munich Faculty of Medicine. Primary endpoint: Number (%) of patients with fully suppressed HIV RNA < 50 copies/mL at week 48. Started Apr 2015; status: terminated.
02
Drugs
darunavirritonavirdolutegravirabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-000360-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000360-34.